- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Clinical, Journal: Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020. (Pubmed Central) - Jan 12, 2022
The total number of insulin treatment visits declined from a peak of 6.0 million visits in 2016 to a nadir of 4.9 million visits in 2020 (approximately 18% decline). In this study, ambulatory insulin use in the United States during the past 5 years remained dominated by the use of insulin analogs and insulin pen delivery devices, with increasing uptake of newer products as they have been brought to market.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
PK/PD data, Preclinical, Journal: Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: Liraglutide, insulin aspart and insulin detemir. (Pubmed Central) - Jan 4, 2022
Finally, more superficial injections resulted in faster absorption, higher C/dose and bioavailability of insulin aspart (p<0.05, 3.0 vs. 5.0 mm injection depth). In conclusion, pig breed and injection region affected the PK of liraglutide, insulin aspart and insulin detemir and reliable predictions of human PK were demonstrated when applying single-species allometric scaling with the pig as a pre-clinical animal model.
- |||||||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Retrospective data, Journal: Post Hoc Analysis Evaluating the Impact of Antihyperglycemic Background Therapies on Attainment of A1C Targets Without Hypoglycemia in the ACHIEVE Control Pragmatic, Real-Life Study. (Pubmed Central) - Dec 7, 2021
ACHIEVE Control, a prospective, open-label, randomized, pragmatic, real-life study in insulin-naive people with type 2 diabetes (A1C 8.0-11.0%), demonstrated superiority of insulin glargine 300 units/mL (Gla-300) versus first-generation standard-of-care basal insulin (SOC-BI; glargine 100 units/mL or insulin detemir) in achieving individualized A1C targets without documented symptomatic (glucose ≤3.9 mmol/L [≤70 mg/dL] or <3.0 mmol/L [<54 mg/dL]) or severe hypoglycemia (American Diabetes Association level 3) at 6 months...The results suggest that, in insulin-naive people with type 2 diabetes, Gla-300 is effective with a risk of hypoglycemia that is lower than or similar to that of SOC-BI regardless of background medication. Individuals receiving concomitant sulfonylureas were more likely to remain without symptomatic or severe hypoglycemia with Gla-300.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Clinical, Review, Journal: Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. (Pubmed Central) - Dec 2, 2021
If warranted, switching between basal insulins can be done using simple regimens.The dose of basal insulin should be increased as required up to approximately 0.5-1.0 units/kg/day in some cases. Overbasalization (continuing to escalate dose without a meaningful reduction in fasting plasma glucose) is not recommended; rather re-evaluation of individual therapy, including consideration of more concentrated basal insulin preparations and/or short-acting prandial insulin as well as other glucose-lowering therapies, is suggested.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Selective CNS Targeting and Distribution with a Refined Region-Specific Intranasal Delivery Technique via the Olfactory Mucosa. (Pubmed Central) - Nov 29, 2021
This study successfully demonstrated region-specific administration at the olfactory mucosa resulting in over 20% of the administered fluorescein dose in the olfactory bulbs, and no peripheral bioactivity of insulin detemir and Fc-dependent uptake of two murine IgG1 (11C7 and P3X) along the olfactory pathway to cortex and hippocampus...In summary, it was successfully demonstrated that region-specific intranasal administration via the olfactory region resulted in improved brain targeting and reduced peripheral targeting in mice. The data are discussed with regard to their clinical potential.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P2 trial: DETERMINE: Detemir vs NPH (clinicaltrials.gov) - Nov 18, 2021
P2, N=336, Not yet recruiting,
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Journal: Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update. (Pubmed Central) - Nov 4, 2021
Insulin degludec reduces hypoglycemia risk compared to insulin glargine U100. Future studies should explore the potential for further improvement of treatment results in type 1 diabetes by a structured approach to personalization of basal insulin therapy.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Journal: Facile synthesis of insulin fusion derivatives through sortase A ligation. (Pubmed Central) - Oct 1, 2021
We further demonstrated that a new insulin derivative synthesized by this SrtA-mediated ligation shows strong cellular and in vivo bioactivity. This enzymatic method can therefore be used for future insulin design and development.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
[VIRTUAL] How did we get here? An overview of therapeutic insulin over the past 100 years (Channel 1) - Sep 30, 2021 - Abstract #IDF2021IDF_11;
The future lies with regenerative medicine with the use of islet cells from different sources or in combination including: production of islet B-cells from embryonic stem cells, multiplication of islet B-cells from harvested islet B-cells or induced from pancreatic duct cells, use of donor pancreas, with enhanced multiplication and growth of islet B-cells; use of animal derived islet B-cells, with enhanced multiplication and growth, and antigenic modification; provision of islet B-cell cultures in partially permeable pouches. Learning Objectives 1) Understand the scientific build up to the discovery of insulin 2) Describe the evolution of therapeutic insulin 3) Recognize the future development of therapeutic insulin
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment open, Combination therapy: Afrezza (clinicaltrials.gov) - Sep 21, 2021
P3, N=264, Recruiting,
Current use of long-acting insulin analogs is not associated with a reduced risk of MACE compared to use of NPH insulin among patients with type 2 diabetes. Not yet recruiting --> Recruiting
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion date, Trial primary completion date: CF-IDEA: Cystic Fibrosis - Insulin Deficiency, Early Action (clinicaltrials.gov) - Sep 16, 2021
P3, N=100, Recruiting,
Not yet recruiting --> Recruiting Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Dec 2020 --> Dec 2022
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion date, Trial primary completion date: IDIOM: Insulin Detemir in Obesity Management (clinicaltrials.gov) - Sep 9, 2021
P=N/A, N=240, Active, not recruiting,
The method was applied to13 forensic cases in which insulin use was suspected. Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion date, Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Aug 23, 2021
P3, N=264, Not yet recruiting,
Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022 Trial completion date: Apr 2025 --> Apr 2024 | Trial primary completion date: Apr 2024 --> Apr 2023
- |||||||||| Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Journal: Predictors of Self-Efficacy in Administering Insulin Injection. (Pubmed Central) - Aug 20, 2021
The findings indicated that "knowledge of diabetes and insulin injection," "insulin injection skills," "senior high school or above education," and "diabetes duration" were predictors of self-efficacy in administering insulin injection, which explained 41% of the total variance in self-efficacy. Health care professionals can design relevant strategies for improving patient self-efficacy in administering insulin injection, thereby increasing patients' insulin self-injection abilities.
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Clinical, Review, Journal: Recent updates in the Alzheimer's disease etiopathology and possible treatment approaches: a narrative review of current clinical trials. (Pubmed Central) - Aug 15, 2021
It is predicted that some FDA-approved drugs such as Paracetamol, Risperidone, Escitalopram, Simvastatin, Cilostazoand, and Ritalin-SR could also use in off-label ways for AD. This review improves our ability to recognize novel treatments for AD and suggesting approaches for the clinical trial design for this devastating disease in the near future.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Clinical, Review, Journal, Real-world evidence: Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: a review of the DELIVER programme. (Pubmed Central) - Aug 8, 2021
Evidence from randomized controlled trials (RCTs) has shown that second-generation basal insulin (BI) analogues, insulin glargine 300 U/mL (Gla-300) and insulin degludec (IDeg), provide similar glycaemic control, with a lower risk of hypoglycaemia compared with the first-generation BI analogue insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes (T2D)...Overall, Gla-300 provided similar antihyperglycaemic effectiveness and a lower risk of hypoglycaemia versus the first-generation BI analogues Gla-100 and insulin detemir in people with T2D who had switched BIs...In addition, the DELIVER 2 study reported that people with T2D who switched to Gla-300 had reduced healthcare resource utilisation, with an overall saving of US$1439 per-person per-year, compared with those who switched to another BI analogue. Overall, the real-world DELIVER programme demonstrated that the glycaemic control with low risk of hypoglycaemia observed with Gla-300 in RCTs was also seen in standard clinical practice.
- |||||||||| Xolair (omalizumab) / Roche, Novartis
Clinical, Journal: The complexities of insulin allergy: a case and approach. (Pubmed Central) - Jul 31, 2021
Therapeutic strategies include avoidance and insulin alternatives, alternate insulin preparations, or desensitization. In severe recurrent hypersensitivity reactions, Omalizumab or pancreatic transplantation have been effective.
- |||||||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics (clinicaltrials.gov) - Jul 30, 2021
P=N/A, N=103951, Completed,
In severe recurrent hypersensitivity reactions, Omalizumab or pancreatic transplantation have been effective. Active, not recruiting --> Completed
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Journal: Financial advantage or barrier when deprescribing for seniors: A case based analysis. (Pubmed Central) - Jul 30, 2021
The scenarios demonstrated a small impact on the pharmacy's gross margin, in some cases a significant financial impact on patient costs, but minimal impact to government. Deprescribing initiatives and policies should include financial considerations for pharmacies and patients.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Journal, HEOR: Detemir versus Neutral Protamine Hagedorn Insulin for Diabetes Mellitus in Pregnancy: A Comparative-Effectiveness, Randomized Controlled Trial. (Pubmed Central) - Jul 24, 2021
P4
Bayesian analysis indicated an 87% posterior probability of reduced primary outcome with insulin detemir relative to NPH (posterior adjusted relative risk, 0.88, 95% credible interval, 0.61 - 1.12). Bayesian analyses for secondary outcomes showed consistent findings of lower adverse maternal outcomes with use of insulin detemir vs NPH, e.g. maternal hypoglycemic events (97% probability of benefit, posterior adjusted relative risk 0.59, 95% credible interval, 0.29 - 1.08), and hypertensive disorders (88% probability of benefit, posterior adjusted relative risk 0.81, 95% credible interval 0.54 - 1.16) In our comparative effectiveness trial involving individuals with type 2 diabetes or overt type 2, use of insulin detemir compared to NPH resulted in lower rates of adverse neonatal and maternal outcomes.
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
New P3 trial, Combination therapy: Afrezza (clinicaltrials.gov) - Jul 22, 2021
P3, N=264, Not yet recruiting,
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Levemir out loud! (Twitter) - Jul 8, 2021
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk, Byetta (exenatide) / AstraZeneca
Clinical, Review, Journal: Using RWE research to extend clinical trials in diabetes: An example with implications for the future. (Pubmed Central) - Jun 26, 2021
Thus, the aim of this review is to discuss, within the context of randomized and observational studies, the clinical effects of insulin degludec use in type 1 and type 2 diabetes. Despite numerous challenges, RWE can be used to complement evidence from RCTs.
|
